Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity
Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss
Sensorion Announces the Appointment of Laurene Danon as Chief Financial Officer
Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Sensorion Announces its Participation in Upcoming Investor Conferences in June 2024
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 29, 2024
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025
Sensorion Reports Full-Year 2023 Financial Results and Business Update
Sensorion Announces the Availability of its Financial Report for 2023